{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "b2e00b85",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os, sys\n",
    "from dotenv import load_dotenv\n",
    "load_dotenv()\n",
    "\n",
    "GOOGLE_API_KEY = os.getenv(\"GOOGLE_API_KEY\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "18f2c963",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Gemini api key set successfully.\n"
     ]
    }
   ],
   "source": [
    "try:\n",
    "    os.environ[\"GOOGLE_API_KEY\"] = GOOGLE_API_KEY\n",
    "    os.environ[\"GOOGLE_GENAI_USE_VERTEXAI\"] = \"FALSE\"\n",
    "    print(\"Gemini api key set successfully.\")\n",
    "except Exception as e:\n",
    "    print(\"Error setting Gemini api key:\", e)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "939498e3",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "✅ ADK components imported successfully.\n"
     ]
    }
   ],
   "source": [
    "from typing import Any, Dict\n",
    "\n",
    "from google.adk.agents import Agent, LlmAgent\n",
    "from google.adk.apps.app import App, EventsCompactionConfig\n",
    "from google.adk.models.google_llm import Gemini\n",
    "from google.adk.sessions import DatabaseSessionService\n",
    "from google.adk.sessions import InMemorySessionService\n",
    "from google.adk.runners import Runner\n",
    "from google.adk.tools.tool_context import ToolContext\n",
    "from google.genai import types\n",
    "\n",
    "print(\"✅ ADK components imported successfully.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "f3dddffe",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "✅ Helper functions defined.\n"
     ]
    }
   ],
   "source": [
    "# Define helper functions that will be reused throughout the notebook\n",
    "async def run_session(\n",
    "    runner_instance: Runner,\n",
    "    user_queries: list[str] | str = None,\n",
    "    session_name: str = \"default\",\n",
    "):\n",
    "    print(f\"\\n ### Session: {session_name}\")\n",
    "\n",
    "    # Get app name from the Runner\n",
    "    app_name = runner_instance.app_name\n",
    "\n",
    "    # Attempt to create a new session or retrieve an existing one\n",
    "    try:\n",
    "        session = await session_service.create_session(\n",
    "            app_name=app_name, user_id=USER_ID, session_id=session_name\n",
    "        )\n",
    "    except:\n",
    "        session = await session_service.get_session(\n",
    "            app_name=app_name, user_id=USER_ID, session_id=session_name\n",
    "        )\n",
    "\n",
    "    # Process queries if provided\n",
    "    if user_queries:\n",
    "        # Convert single query to list for uniform processing\n",
    "        if type(user_queries) == str:\n",
    "            user_queries = [user_queries]\n",
    "\n",
    "        # Process each query in the list sequentially\n",
    "        for query in user_queries:\n",
    "            print(f\"\\nUser > {query}\")\n",
    "\n",
    "            # Convert the query string to the ADK Content format\n",
    "            query = types.Content(role=\"user\", parts=[types.Part(text=query)])\n",
    "\n",
    "            # Stream the agent's response asynchronously\n",
    "            async for event in runner_instance.run_async(\n",
    "                user_id=USER_ID, session_id=session.id, new_message=query\n",
    "            ):\n",
    "                # Check if the event contains valid content\n",
    "                if event.content and event.content.parts:\n",
    "                    # Filter out empty or \"None\" responses before printing\n",
    "                    if (\n",
    "                        event.content.parts[0].text != \"None\"\n",
    "                        and event.content.parts[0].text\n",
    "                    ):\n",
    "                        print(f\"{MODEL_NAME} > \", event.content.parts[0].text)\n",
    "    else:\n",
    "        print(\"No queries!\")\n",
    "\n",
    "\n",
    "print(\"✅ Helper functions defined.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "afdd6a53",
   "metadata": {},
   "outputs": [],
   "source": [
    "retry_config = types.HttpRetryOptions(\n",
    "    attempts=5,  # Maximum retry attempts\n",
    "    exp_base=7,  # Delay multiplier\n",
    "    initial_delay=1,\n",
    "    http_status_codes=[429, 500, 503, 504],  # Retry on these HTTP errors\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "52da2239",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "✅ Stateful agent initialized!\n",
      "   - Application: default\n",
      "   - User: default\n",
      "   - Using: InMemorySessionService\n"
     ]
    }
   ],
   "source": [
    "APP_NAME = \"default\"  # Application\n",
    "USER_ID = \"default\"  # User\n",
    "SESSION = \"default\"  # Session\n",
    "\n",
    "MODEL_NAME = \"gemini-2.5-flash-lite\"\n",
    "\n",
    "\n",
    "# Step 1: Create the LLM Agent\n",
    "root_agent = Agent(\n",
    "    model=Gemini(model=\"gemini-2.5-flash-lite\", retry_options=retry_config),\n",
    "    name=\"text_chat_bot\",\n",
    "    description=\"A text chatbot\",  # Description of the agent's purpose\n",
    ")\n",
    "\n",
    "# Step 2: Set up Session Management\n",
    "# InMemorySessionService stores conversations in RAM (temporary)\n",
    "session_service = InMemorySessionService()\n",
    "\n",
    "# Step 3: Create the Runner\n",
    "runner = Runner(agent=root_agent, app_name=APP_NAME, session_service=session_service)\n",
    "\n",
    "print(\"✅ Stateful agent initialized!\")\n",
    "print(f\"   - Application: {APP_NAME}\")\n",
    "print(f\"   - User: {USER_ID}\")\n",
    "print(f\"   - Using: {session_service.__class__.__name__}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "9936b21b",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " ### Session: stateful-agentic-session\n",
      "\n",
      "User > Hi, I am Manan! What is the capital of United States?\n",
      "gemini-2.5-flash-lite >  Hello Manan! The capital of the United States is Washington, D.C.\n",
      "\n",
      "User > Hello! What is my name?\n",
      "gemini-2.5-flash-lite >  Hello! Your name is Manan.\n"
     ]
    }
   ],
   "source": [
    "# Run a conversation with two queries in the same session\n",
    "# Notice: Both queries are part of the SAME session, so context is maintained\n",
    "await run_session(\n",
    "    runner,\n",
    "    [\n",
    "        \"Hi, I am Manan! What is the capital of United States?\",\n",
    "        \"Hello! What is my name?\",  # This time, the agent should remember!\n",
    "    ],\n",
    "    \"stateful-agentic-session\",\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "6cd18d44",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " ### Session: stateful-agentic-session\n",
      "\n",
      "User > What did I ask you about earlier?\n",
      "gemini-2.5-flash-lite >  You asked me what the capital of the United States is, and you told me your name is Manan.\n",
      "\n",
      "User > And remind me, what's my name?\n",
      "gemini-2.5-flash-lite >  Your name is Manan.\n"
     ]
    }
   ],
   "source": [
    "# Run this cell after restarting the kernel. All this history will be gone...\n",
    "await run_session(\n",
    "    runner,\n",
    "    [\"What did I ask you about earlier?\", \"And remind me, what's my name?\"],\n",
    "    \"stateful-agentic-session\",\n",
    ")  # Note, we are using same session name"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "f64427db",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "✅ Upgraded to persistent sessions!\n",
      "   - Database: my_agent_data.db\n",
      "   - Sessions will survive restarts!\n"
     ]
    }
   ],
   "source": [
    "# Step 1: Create the same agent (notice we use LlmAgent this time)\n",
    "chatbot_agent = LlmAgent(\n",
    "    model=Gemini(model=\"gemini-2.5-flash-lite\", retry_options=retry_config),\n",
    "    name=\"text_chat_bot\",\n",
    "    description=\"A text chatbot with persistent memory\",\n",
    ")\n",
    "\n",
    "# Step 2: Switch to DatabaseSessionService\n",
    "# SQLite database will be created automatically\n",
    "db_url = \"sqlite:///my_agent_data.db\"  # Local SQLite file\n",
    "session_service = DatabaseSessionService(db_url=db_url)\n",
    "\n",
    "# Step 3: Create a new runner with persistent storage\n",
    "runner = Runner(agent=chatbot_agent, app_name=APP_NAME, session_service=session_service)\n",
    "\n",
    "print(\"✅ Upgraded to persistent sessions!\")\n",
    "print(f\"   - Database: my_agent_data.db\")\n",
    "print(f\"   - Sessions will survive restarts!\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "da280f20",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " ### Session: test-db-session-01\n",
      "\n",
      "User > Hi, I am Manan! What is the capital of the United States?\n",
      "gemini-2.5-flash-lite >  Hi Manan! The capital of the United States is Washington, D.C.\n",
      "\n",
      "User > Hello! What is my name?\n",
      "gemini-2.5-flash-lite >  Your name is Manan.\n"
     ]
    }
   ],
   "source": [
    "await run_session(\n",
    "    runner,\n",
    "    [\"Hi, I am Manan! What is the capital of the United States?\", \"Hello! What is my name?\"],\n",
    "    \"test-db-session-01\",\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "0df1bb03",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " ### Session: test-db-session-01\n",
      "\n",
      "User > What is the capital of India?\n",
      "gemini-2.5-flash-lite >  The capital of India is New Delhi.\n",
      "\n",
      "User > Hello! What is my name?\n",
      "gemini-2.5-flash-lite >  Your name is Manan.\n"
     ]
    }
   ],
   "source": [
    "await run_session(\n",
    "    runner,\n",
    "    [\"What is the capital of India?\", \"Hello! What is my name?\"],\n",
    "    \"test-db-session-01\",\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "dcbc79a5",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " ### Session: test-db-session-02\n",
      "\n",
      "User > Hello! What is my name?\n",
      "gemini-2.5-flash-lite >  I do not have access to your personal information, including your name. I am a text chatbot and do not have the ability to store or recall user data.\n"
     ]
    }
   ],
   "source": [
    "await run_session(\n",
    "    runner, [\"Hello! What is my name?\"], \"test-db-session-02\"\n",
    ")  # Note, we are using new session name"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "3410bd9e",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['app_name', 'session_id', 'author', 'content']\n",
      "('default', 'test-db-session-01', 'user', '{\"parts\": [{\"text\": \"Hi, I am Sam! What is the capital of the United States?\"}], \"role\": \"user\"}')\n",
      "('default', 'test-db-session-01', 'text_chat_bot', '{\"parts\": [{\"text\": \"Hi Sam! The capital of the United States is Washington, D.C.\"}], \"role\": \"model\"}')\n",
      "('default', 'test-db-session-01', 'user', '{\"parts\": [{\"text\": \"Hello! What is my name?\"}], \"role\": \"user\"}')\n",
      "('default', 'test-db-session-01', 'text_chat_bot', '{\"parts\": [{\"text\": \"Your name is Sam.\"}], \"role\": \"model\"}')\n",
      "('default', 'test-db-session-01', 'user', '{\"parts\": [{\"text\": \"Hi, I am Manan! What is the capital of the United States?\"}], \"role\": \"user\"}')\n",
      "('default', 'test-db-session-01', 'text_chat_bot', '{\"parts\": [{\"text\": \"Hi Manan! The capital of the United States is Washington, D.C.\"}], \"role\": \"model\"}')\n",
      "('default', 'test-db-session-01', 'user', '{\"parts\": [{\"text\": \"Hello! What is my name?\"}], \"role\": \"user\"}')\n",
      "('default', 'test-db-session-01', 'text_chat_bot', '{\"parts\": [{\"text\": \"Your name is Manan.\"}], \"role\": \"model\"}')\n",
      "('default', 'test-db-session-01', 'user', '{\"parts\": [{\"text\": \"What is the capital of India?\"}], \"role\": \"user\"}')\n",
      "('default', 'test-db-session-01', 'text_chat_bot', '{\"parts\": [{\"text\": \"The capital of India is New Delhi.\"}], \"role\": \"model\"}')\n",
      "('default', 'test-db-session-01', 'user', '{\"parts\": [{\"text\": \"Hello! What is my name?\"}], \"role\": \"user\"}')\n",
      "('default', 'test-db-session-01', 'text_chat_bot', '{\"parts\": [{\"text\": \"Your name is Manan.\"}], \"role\": \"model\"}')\n",
      "('default', 'test-db-session-01', 'user', '{\"parts\": [{\"text\": \"I want to test your memory. My mom is Barkha Jain and my dad is Manoj Jain. They live in Panipat. I am currently in Chicago.\"}], \"role\": \"user\"}')\n",
      "('default', 'test-db-session-01', 'text_chat_bot', '{\"parts\": [{\"text\": \"I will remember that your mom is Barkha Jain and your dad is Manoj Jain. I will also remember that they live in Panipat and you are currently in Chicago.\"}], \"role\": \"model\"}')\n",
      "('default', 'test-db-session-01', 'user', '{\"parts\": [{\"text\": \"Can you remember all my personal details?\"}], \"role\": \"user\"}')\n",
      "('default', 'test-db-session-01', 'text_chat_bot', '{\"parts\": [{\"text\": \"Yes, I can remember your personal details, including:\\\\n\\\\n*   Your name: Manan\\\\n*   Your mom\\'s name: Barkha Jain\\\\n*   Your dad\\'s name: Manoj Jain\\\\n*   Where your parents live: Panipat\\\\n*   Where you are currently: Chicago\"}], \"role\": \"model\"}')\n",
      "('default', 'test-db-session-01', 'user', '{\"parts\": [{\"text\": \"Ok so can you tell me my parents approximate address?\"}], \"role\": \"user\"}')\n",
      "('default', 'test-db-session-01', 'text_chat_bot', '{\"parts\": [{\"text\": \"I can remember that your parents live in Panipat, but I don\\'t have their approximate address. I only have the city information you provided.\"}], \"role\": \"model\"}')\n",
      "('default', 'test-db-session-01', 'user', '{\"parts\": [{\"text\": \"And what about the city information about my parents? give me all information that you have on the city\"}], \"role\": \"user\"}')\n",
      "('default', 'test-db-session-01', 'text_chat_bot', '{\"parts\": [{\"text\": \"I have the city information that your parents live in **Panipat**.\"}], \"role\": \"model\"}')\n",
      "('default', 'test-db-session-02', 'user', '{\"parts\": [{\"text\": \"Hello! What is my name?\"}], \"role\": \"user\"}')\n",
      "('default', 'test-db-session-02', 'text_chat_bot', '{\"parts\": [{\"text\": \"I do not have access to your personal information, including your name. I am a text chatbot and do not have the ability to store or recall user data.\"}], \"role\": \"model\"}')\n",
      "('research_app_compacting', 'compaction_demo', 'user', '{\"parts\": [{\"text\": \"What is the latest news about AI in healthcare?\"}], \"role\": \"user\"}')\n",
      "('research_app_compacting', 'compaction_demo', 'text_chat_bot', '{\"parts\": [{\"text\": \"Here\\'s a summary of some of the latest developments and trends in AI in healthcare:\\\\n\\\\n**Key Areas of Advancement:**\\\\n\\\\n*   **Drug Discovery and Development:** AI is revolutionizing how new drugs are found and tested.\\\\n    *   **Accelerated Research:** AI algorithms can sift through vast datasets of biological information to identify potential drug candidates much faster than traditional methods.\\\\n    *   **Personalized Medicine:** AI is helping to predict how individual patients will respond to different treatments, paving the way for more personalized and effective therapies.\\\\n    *   **Clinical Trial Optimization:** AI can help identify suitable patients for clinical trials and predict trial outcomes, making the process more efficient and cost-effective.\\\\n*   **Medical Imaging and Diagnostics:** AI continues to make significant strides in analyzing medical images.\\\\n    *   **Enhanced Accuracy:** AI models are becoming increasingly proficient at detecting subtle anomalies in X-rays, CT scans, MRIs, and other imaging modalities, often at a level comparable to or exceeding human radiologists.\\\\n    *   **Early Disease Detection:** AI can help identify early signs of diseases like cancer, diabetic retinopathy, and cardiovascular issues, leading to earlier intervention and better prognoses.\\\\n    *   **Workflow Improvements:** AI can automate the initial screening of images, freeing up radiologists to focus on more complex cases and reducing turnaround times.\\\\n*   **Personalized Treatment and Patient Management:**\\\\n    *   **Predictive Analytics:** AI models can predict patient risk for certain conditions, hospital readmissions, or adverse events, allowing healthcare providers to intervene proactively.\\\\n    *   **Virtual Assistants and Chatbots:** AI-powered chatbots are being used for patient onboarding, answering common questions, scheduling appointments, and providing health reminders, improving patient engagement and reducing administrative burden.\\\\n    *   **Remote Patient Monitoring:** AI can analyze data from wearable devices and other sensors to monitor patients remotely, alerting clinicians to potential issues.\\\\n*   **Administrative and Operational Efficiency:**\\\\n    *   **Streamlined Workflows:** AI is automating tasks like medical coding, billing, and scheduling, freeing up healthcare professionals\\' time.\\\\n    *   **Resource Optimization:** AI can help hospitals manage resources like staff, equipment, and bed availability more efficiently.\\\\n    *   **Fraud Detection:** AI is being used to identify fraudulent claims and billing practices.\\\\n\\\\n**Recent Trends and Focus Areas:**\\\\n\\\\n*   **Generative AI in Healthcare:** Large Language Models (LLMs) are showing promise in areas like:\\\\n    *   **Clinical Documentation:** Summarizing patient visits, generating discharge summaries, and assisting with note-taking.\\\\n    *   **Medical Education:** Creating training materials and simulating patient scenarios.\\\\n    *   **Patient Communication:** Drafting responses to patient inquiries (under strict human oversight).\\\\n    *   **Research Summarization:** Helping researchers digest large volumes of scientific literature.\\\\n*   **Explainable AI (XAI):** As AI becomes more integrated into critical healthcare decisions, there\\'s a growing emphasis on making AI models transparent and understandable, allowing clinicians to trust and validate their outputs.\\\\n*   **Ethical Considerations and Regulation:** With the rapid advancements, there\\'s a continuous discussion and development around ethical guidelines, data privacy, bias mitigation, and regulatory frameworks for AI in healthcare. Ensuring equitable access and preventing exacerbation of health disparities is a major focus.\\\\n*   **AI for Mental Health:** AI is being explored for early detection of mental health conditions, personalized therapy recommendations, and providing accessible support through digital platforms.\\\\n*   **AI in Genomics:** AI is crucial for analyzing complex genomic data to understand disease predispositions, identify therapeutic targets, and advance precision medicine.\\\\n\\\\n**Challenges and Future Outlook:**\\\\n\\\\nDespite the rapid progress, challenges remain, including:\\\\n\\\\n*   **Data Privacy and Security:** Protecting sensitive patient data is paramount.\\\\n*   **Bias in Algorithms:** Ensuring AI models are fair and do not perpetuate existing health disparities.\\\\n*   **Regulatory Hurdles:** Navigating the complex landscape of healthcare regulations for AI adoption.\\\\n*   **Integration into Clinical Workflows:** Seamlessly incorporating AI tools into existing healthcare systems and training healthcare professionals.\\\\n*   **Cost and Accessibility:** Making AI solutions affordable and accessible to all healthcare providers and patients.\\\\n\\\\nThe future of AI in healthcare is incredibly promising, with the potential to transform how we prevent, diagnose, and treat diseases, leading to more efficient, personalized, and accessible care.\"}], \"role\": \"model\"}')\n",
      "('research_app_compacting', 'compaction_demo', 'user', '{\"parts\": [{\"text\": \"Are there any new developments in drug discovery?\"}], \"role\": \"user\"}')\n",
      "('research_app_compacting', 'compaction_demo', 'text_chat_bot', '{\"parts\": [{\"text\": \"Yes, there are *constant* new developments in drug discovery, and AI is a major driving force behind many of them. Here\\'s a breakdown of some of the most exciting recent advancements:\\\\n\\\\n**AI-Powered Breakthroughs:**\\\\n\\\\n*   **Accelerated Target Identification:** AI algorithms are becoming incredibly sophisticated at analyzing vast datasets (genomic, proteomic, clinical, scientific literature) to identify novel biological targets that are implicated in diseases. This significantly speeds up the initial, often time-consuming, phase of drug discovery.\\\\n    *   **Example:** Companies are using AI to predict which proteins are most likely to be effective drug targets for specific cancers or neurological disorders.\\\\n*   **De Novo Drug Design:** Instead of screening existing libraries of compounds, AI can now *design entirely new molecules* from scratch that are optimized to bind to a specific target and have desired pharmacological properties (efficacy, safety, solubility).\\\\n    *   **Example:** Generative AI models can create novel chemical structures with a high probability of success, drastically reducing the number of compounds that need to be synthesized and tested.\\\\n*   **Predicting Compound Efficacy and Toxicity:** AI models can predict how well a potential drug will work and what its side effects might be *before* it\\'s even synthesized. This helps researchers prioritize the most promising candidates and de-prioritize those likely to fail, saving immense time and resources.\\\\n    *   **Example:** AI is being used to predict off-target effects or potential liver toxicity of drug candidates early in the process.\\\\n*   **Repurposing Existing Drugs:** AI can analyze existing drugs and their known mechanisms of action to identify new therapeutic uses for them. This is a faster and less expensive route to new treatments as safety profiles are already established.\\\\n    *   **Example:** AI has been used to identify existing drugs that might be effective against emerging infectious diseases or rare genetic disorders.\\\\n*   **Optimizing Clinical Trial Design:** AI can analyze historical clinical trial data and real-world evidence to help design more efficient and effective trials, including identifying the right patient populations and predicting trial outcomes.\\\\n\\\\n**Specific Examples and Companies to Watch:**\\\\n\\\\n*   **Insilico Medicine:** This company has been a pioneer, using AI for end-to-end drug discovery, from target identification to molecule design. They\\'ve had several AI-discovered drug candidates enter clinical trials.\\\\n*   **Exscientia:** Another leader in AI-driven drug discovery, Exscientia focuses on designing novel molecules for various therapeutic areas and has entered into significant partnerships with major pharmaceutical companies.\\\\n*   **Recursion Pharmaceuticals:** Recursion uses AI and automation to map human cellular responses to diseases and potential drugs, looking for novel therapeutic interventions.\\\\n*   **Alphabet\\'s DeepMind (AlphaFold):** While not directly a drug discovery company, AlphaFold\\'s ability to predict protein structures with unprecedented accuracy is a game-changer. Knowing a protein\\'s 3D shape is crucial for understanding its function and designing drugs that can interact with it. This has accelerated research for many drug discovery efforts.\\\\n*   **Relay Therapeutics:** They focus on using a combination of experimental and computational approaches, including AI, to understand protein motion and design better drugs.\\\\n\\\\n**Emerging Trends:**\\\\n\\\\n*   **Focus on Undruggable Targets:** AI is increasingly being applied to tackle diseases caused by \\\\\"undruggable\\\\\" targets \\\\u2013 proteins that have been historically difficult to design drugs for due to their complex structures or functions.\\\\n*   **AI in Antibody Discovery:** AI is accelerating the discovery and engineering of therapeutic antibodies, which are a major class of drugs.\\\\n*   **Personalized Drug Discovery:** While still nascent, AI holds the promise of enabling drug discovery tailored to an individual\\'s genetic makeup or disease profile.\\\\n\\\\n**In summary, AI is not just augmenting drug discovery; it\\'s fundamentally transforming it by making the process faster, more efficient, and capable of exploring entirely new frontiers in molecular design and therapeutic intervention.**\"}], \"role\": \"model\"}')\n",
      "('research_app_compacting', 'compaction_demo', 'user', '{\"parts\": [{\"text\": \"Tell me more about the second development you found.\"}], \"role\": \"user\"}')\n",
      "('research_app_compacting', 'compaction_demo', 'text_chat_bot', '{\"parts\": [{\"text\": \"You\\'re likely referring to **De Novo Drug Design** when you ask about the \\\\\"second development\\\\\" in drug discovery. This is indeed one of the most transformative areas where AI is making a significant impact.\\\\n\\\\nLet me elaborate on **De Novo Drug Design:**\\\\n\\\\n**What is De Novo Drug Design?**\\\\n\\\\nTraditionally, drug discovery involved:\\\\n1.  **Target Identification:** Finding the biological molecule (like a protein) involved in a disease.\\\\n2.  **Library Screening:** Testing thousands or millions of existing chemical compounds (from large libraries) to see if any bind to the target.\\\\n3.  **Lead Optimization:** Taking promising \\\\\"hits\\\\\" from screening and modifying them to improve their properties.\\\\n\\\\n**De Novo drug design** (from Latin, meaning \\\\\"from the beginning\\\\\") bypasses the extensive library screening. Instead, it uses AI algorithms to **generate entirely new molecular structures** that are specifically designed to interact with a given biological target and possess desired drug-like properties.\\\\n\\\\n**How AI Enables De Novo Design:**\\\\n\\\\nAI models, particularly **generative models**, are the core of this process. Think of them as highly intelligent \\\\\"molecular architects.\\\\\" Here\\'s how they work:\\\\n\\\\n1.  **Learning Molecular Language:** AI models are trained on vast datasets of known molecules, their structures, properties, and how they interact with biological targets. This allows them to learn the \\\\\"language\\\\\" of chemistry and understand the rules that govern molecular behavior and drug-likeness.\\\\n2.  **Defining Design Criteria:** Researchers specify the desired characteristics of the molecule they want to create. This includes:\\\\n    *   **Binding Affinity:** How strongly it should bind to the target protein.\\\\n    *   **Selectivity:** How specifically it should bind to the target without hitting other unintended targets (reducing side effects).\\\\n    *   **Pharmacokinetic Properties (ADMET):** How the drug will be Absorbed, Distributed, Metabolized, Excreted, and its Toxicity profile.\\\\n    *   **Synthesizability:** The likelihood that the molecule can actually be created in a lab.\\\\n3.  **Generating Novel Molecules:** Using techniques like **Generative Adversarial Networks (GANs)**, **Variational Autoencoders (VAEs)**, or **Reinforcement Learning**, the AI proposes novel chemical structures that are predicted to meet these criteria.\\\\n    *   **GANs:** One part of the AI (the \\\\\"generator\\\\\") creates candidate molecules, while another part (the \\\\\"discriminator\\\\\") tries to distinguish between real molecules and AI-generated ones. Through this adversarial process, the generator gets better and better at creating realistic and effective molecules.\\\\n    *   **VAEs:** These models learn a compressed representation (latent space) of molecular structures and can then decode points in this space into new, diverse molecules.\\\\n    *   **Reinforcement Learning:** The AI explores the chemical space, receiving \\\\\"rewards\\\\\" for generating molecules that meet the design criteria and \\\\\"penalties\\\\\" for those that don\\'t, learning to optimize its generation strategy.\\\\n4.  **Iteration and Refinement:** The process is iterative. The AI generates molecules, they are evaluated (often using AI-based prediction models or initial experimental validation), and the feedback is used to refine the generation process.\\\\n\\\\n**Key Advantages of De Novo Drug Design:**\\\\n\\\\n*   **Speed:** It dramatically accelerates the hit-finding phase, moving from concept to potential drug candidate much faster than traditional methods.\\\\n*   **Novelty:** It can discover entirely new chemical scaffolds that might not have been conceived of through human intuition or existing libraries.\\\\n*   **Optimization:** It\\'s not just about finding a binder; it\\'s about designing molecules with optimized drug-like properties from the outset.\\\\n*   **Reduced Costs:** By prioritizing more promising candidates and avoiding extensive trial-and-error with less likely compounds, it can significantly reduce R&D expenses.\\\\n*   **Tackling Difficult Targets:** It offers a powerful approach for designing drugs against \\\\\"undruggable\\\\\" targets that have proven challenging for traditional methods.\\\\n\\\\n**Challenges:**\\\\n\\\\n*   **Synthesizability:** Ensuring the generated molecules can actually be synthesized in a lab is still a key challenge, though AI is also being used to predict and optimize synthetic routes.\\\\n*   **Validation:** Experimental validation is still crucial to confirm the AI\\'s predictions.\\\\n*   **Data Quality:** The performance of AI models heavily relies on the quality and comprehensiveness of the training data.\\\\n\\\\n**In essence, de novo drug design powered by AI represents a paradigm shift, moving from searching for drugs to creating them with precision and intent.** It\\'s a rapidly evolving field that holds immense promise for bringing new medicines to patients faster.\"}], \"role\": \"model\"}')\n",
      "('research_app_compacting', 'compaction_demo', 'user', '{\"parts\": [{\"text\": \"Who are the main companies involved in that?\"}], \"role\": \"user\"}')\n",
      "('research_app_compacting', 'compaction_demo', 'user', None)\n",
      "('research_app_compacting', 'compaction_demo', 'text_chat_bot', '{\"parts\": [{\"text\": \"The landscape of companies involved in de novo drug design is dynamic and growing, encompassing both specialized AI-driven biotech firms and established pharmaceutical giants leveraging these technologies. Here are some of the key players and categories:\\\\n\\\\n**1. Dedicated AI-Driven Drug Discovery Companies:** These companies were built from the ground up with AI at their core.\\\\n\\\\n*   **Insilico Medicine:** A major player that uses its AI platform to cover the entire drug discovery pipeline, from target identification to drug candidate generation and preclinical development. They have advanced several AI-discovered candidates into clinical trials.\\\\n*   **Exscientia:** Another leader focused on AI-driven design of novel molecules. They partner extensively with large pharmaceutical companies and have a pipeline of AI-designed drugs in development.\\\\n*   **Atomwise:** They use deep learning for small molecule drug discovery, including de novo design, and have collaborations with numerous research institutions and pharmaceutical companies.\\\\n*   **Recursion Pharmaceuticals:** While their platform is broader, integrating AI with automation to map cellular biology and discover therapies, de novo design is a component of their approach to identifying novel drug candidates.\\\\n*   **Schr\\\\u00f6dinger:** Though not exclusively an AI company, Schr\\\\u00f6dinger has a long-standing reputation in computational chemistry and physics-based drug discovery. They have increasingly integrated machine learning and AI into their platform for de novo design and property prediction.\\\\n*   **Relay Therapeutics:** Focuses on understanding protein motion and using computational approaches, including AI, to design novel therapeutics.\\\\n*   **Nuritas:** Uses AI and machine learning to discover novel peptides with therapeutic potential, often from natural sources, but the discovery and optimization involve AI-driven design principles.\\\\n\\\\n**2. Major Pharmaceutical Companies Adopting AI for De Novo Design:** The \\\\\"Big Pharma\\\\\" are heavily investing in and collaborating with AI companies, or building their own internal AI capabilities.\\\\n\\\\n*   **Pfizer:** Has been actively exploring AI for various aspects of drug discovery, including de novo design.\\\\n*   **Novartis:** Has a strong focus on digital transformation and AI, with initiatives in AI-driven drug discovery.\\\\n*   **Merck:** Is investing in AI and machine learning to accelerate its R&D efforts, including molecule design.\\\\n*   **Johnson & Johnson:** Has several collaborations and internal teams working on AI for drug discovery.\\\\n*   **AstraZeneca:** Actively utilizes AI and machine learning to enhance its discovery and development processes.\\\\n*   **Roche:** A major player in utilizing computational methods and AI in its R&D.\\\\n*   **Bayer:** Is partnering with AI companies and investing in AI capabilities for drug discovery.\\\\n\\\\n**3. Technology Companies and Cloud Providers Enabling AI Drug Discovery:**\\\\n\\\\nWhile not directly designing drugs, these companies provide the foundational infrastructure and tools that make de novo design possible.\\\\n\\\\n*   **Google (DeepMind):** As mentioned with AlphaFold, their contributions to understanding protein structures are foundational for AI-driven drug design.\\\\n*   **Microsoft:** Offers cloud computing resources and AI tools that are crucial for large-scale drug discovery simulations and model training.\\\\n*   **Amazon Web Services (AWS):** Provides similar cloud infrastructure and AI/ML services.\\\\n\\\\n**4. Academic and Research Institutions:** Many universities and research centers are at the forefront of developing new AI algorithms and methodologies for de novo drug design, often collaborating with industry.\\\\n\\\\n**Key Trends in the Company Landscape:**\\\\n\\\\n*   **Partnerships and Acquisitions:** Large pharma companies frequently partner with or acquire AI-focused biotech firms to gain access to cutting-edge technology.\\\\n*   **In-house AI Teams:** Many large pharmaceutical companies are building significant internal AI/ML teams to develop their own proprietary platforms.\\\\n*   **Focus on Specific Disease Areas:** Some AI companies are specializing in particular therapeutic areas (e.g., oncology, rare diseases) where they can apply their de novo design capabilities.\\\\n*   **Integration with Other AI Applications:** Companies are increasingly looking to integrate de novo design with other AI applications, such as predictive toxicology and clinical trial optimization.\\\\n\\\\nThe field is highly competitive, with constant innovation and new players emerging. It\\'s a space where AI is truly moving from the theoretical to tangible drug candidates entering human trials.\"}], \"role\": \"model\"}')\n",
      "('research_app_compacting', 'compaction_demo', 'user', None)\n"
     ]
    }
   ],
   "source": [
    "import sqlite3\n",
    "\n",
    "def check_data_in_db():\n",
    "    with sqlite3.connect(\"my_agent_data.db\") as connection:\n",
    "        cursor = connection.cursor()\n",
    "        result = cursor.execute(\n",
    "            \"select app_name, session_id, author, content from events\"\n",
    "        )\n",
    "        print([_[0] for _ in result.description])\n",
    "        for each in result.fetchall():\n",
    "            print(each)\n",
    "\n",
    "\n",
    "check_data_in_db()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "63266af1",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "✅ Research App upgraded with Events Compaction!\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\Manan\\AppData\\Local\\Temp\\ipykernel_6212\\3773147741.py:6: UserWarning: [EXPERIMENTAL] EventsCompactionConfig: This feature is experimental and may change or be removed in future versions without notice. It may introduce breaking changes at any time.\n",
      "  events_compaction_config=EventsCompactionConfig(\n"
     ]
    }
   ],
   "source": [
    "# Re-define our app with Events Compaction enabled\n",
    "research_app_compacting = App(\n",
    "    name=\"research_app_compacting\",\n",
    "    root_agent=chatbot_agent,\n",
    "    # This is the new part!\n",
    "    events_compaction_config=EventsCompactionConfig(\n",
    "        compaction_interval=3,  # Trigger compaction every 3 invocations\n",
    "        overlap_size=1,  # Keep 1 previous turn for context\n",
    "    ),\n",
    ")\n",
    "\n",
    "db_url = \"sqlite:///my_agent_data.db\"  # Local SQLite file\n",
    "session_service = DatabaseSessionService(db_url=db_url)\n",
    "\n",
    "# Create a new runner for our upgraded app\n",
    "research_runner_compacting = Runner(\n",
    "    app=research_app_compacting, session_service=session_service\n",
    ")\n",
    "\n",
    "\n",
    "print(\"✅ Research App upgraded with Events Compaction!\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "472f9a83",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " ### Session: compaction_demo\n",
      "\n",
      "User > What is the latest news about AI in healthcare?\n",
      "gemini-2.5-flash-lite >  Here's a summary of some of the latest developments and trends in AI in healthcare:\n",
      "\n",
      "**Key Areas of Advancement:**\n",
      "\n",
      "*   **Drug Discovery and Development:** AI is revolutionizing how new drugs are found and tested.\n",
      "    *   **Accelerated Research:** AI algorithms can sift through vast datasets of biological information to identify potential drug candidates much faster than traditional methods.\n",
      "    *   **Personalized Medicine:** AI is helping to predict how individual patients will respond to different treatments, paving the way for more personalized and effective therapies.\n",
      "    *   **Clinical Trial Optimization:** AI can help identify suitable patients for clinical trials and predict trial outcomes, making the process more efficient and cost-effective.\n",
      "*   **Medical Imaging and Diagnostics:** AI continues to make significant strides in analyzing medical images.\n",
      "    *   **Enhanced Accuracy:** AI models are becoming increasingly proficient at detecting subtle anomalies in X-rays, CT scans, MRIs, and other imaging modalities, often at a level comparable to or exceeding human radiologists.\n",
      "    *   **Early Disease Detection:** AI can help identify early signs of diseases like cancer, diabetic retinopathy, and cardiovascular issues, leading to earlier intervention and better prognoses.\n",
      "    *   **Workflow Improvements:** AI can automate the initial screening of images, freeing up radiologists to focus on more complex cases and reducing turnaround times.\n",
      "*   **Personalized Treatment and Patient Management:**\n",
      "    *   **Predictive Analytics:** AI models can predict patient risk for certain conditions, hospital readmissions, or adverse events, allowing healthcare providers to intervene proactively.\n",
      "    *   **Virtual Assistants and Chatbots:** AI-powered chatbots are being used for patient onboarding, answering common questions, scheduling appointments, and providing health reminders, improving patient engagement and reducing administrative burden.\n",
      "    *   **Remote Patient Monitoring:** AI can analyze data from wearable devices and other sensors to monitor patients remotely, alerting clinicians to potential issues.\n",
      "*   **Administrative and Operational Efficiency:**\n",
      "    *   **Streamlined Workflows:** AI is automating tasks like medical coding, billing, and scheduling, freeing up healthcare professionals' time.\n",
      "    *   **Resource Optimization:** AI can help hospitals manage resources like staff, equipment, and bed availability more efficiently.\n",
      "    *   **Fraud Detection:** AI is being used to identify fraudulent claims and billing practices.\n",
      "\n",
      "**Recent Trends and Focus Areas:**\n",
      "\n",
      "*   **Generative AI in Healthcare:** Large Language Models (LLMs) are showing promise in areas like:\n",
      "    *   **Clinical Documentation:** Summarizing patient visits, generating discharge summaries, and assisting with note-taking.\n",
      "    *   **Medical Education:** Creating training materials and simulating patient scenarios.\n",
      "    *   **Patient Communication:** Drafting responses to patient inquiries (under strict human oversight).\n",
      "    *   **Research Summarization:** Helping researchers digest large volumes of scientific literature.\n",
      "*   **Explainable AI (XAI):** As AI becomes more integrated into critical healthcare decisions, there's a growing emphasis on making AI models transparent and understandable, allowing clinicians to trust and validate their outputs.\n",
      "*   **Ethical Considerations and Regulation:** With the rapid advancements, there's a continuous discussion and development around ethical guidelines, data privacy, bias mitigation, and regulatory frameworks for AI in healthcare. Ensuring equitable access and preventing exacerbation of health disparities is a major focus.\n",
      "*   **AI for Mental Health:** AI is being explored for early detection of mental health conditions, personalized therapy recommendations, and providing accessible support through digital platforms.\n",
      "*   **AI in Genomics:** AI is crucial for analyzing complex genomic data to understand disease predispositions, identify therapeutic targets, and advance precision medicine.\n",
      "\n",
      "**Challenges and Future Outlook:**\n",
      "\n",
      "Despite the rapid progress, challenges remain, including:\n",
      "\n",
      "*   **Data Privacy and Security:** Protecting sensitive patient data is paramount.\n",
      "*   **Bias in Algorithms:** Ensuring AI models are fair and do not perpetuate existing health disparities.\n",
      "*   **Regulatory Hurdles:** Navigating the complex landscape of healthcare regulations for AI adoption.\n",
      "*   **Integration into Clinical Workflows:** Seamlessly incorporating AI tools into existing healthcare systems and training healthcare professionals.\n",
      "*   **Cost and Accessibility:** Making AI solutions affordable and accessible to all healthcare providers and patients.\n",
      "\n",
      "The future of AI in healthcare is incredibly promising, with the potential to transform how we prevent, diagnose, and treat diseases, leading to more efficient, personalized, and accessible care.\n",
      "\n",
      " ### Session: compaction_demo\n",
      "\n",
      "User > Are there any new developments in drug discovery?\n",
      "gemini-2.5-flash-lite >  Yes, there are *constant* new developments in drug discovery, and AI is a major driving force behind many of them. Here's a breakdown of some of the most exciting recent advancements:\n",
      "\n",
      "**AI-Powered Breakthroughs:**\n",
      "\n",
      "*   **Accelerated Target Identification:** AI algorithms are becoming incredibly sophisticated at analyzing vast datasets (genomic, proteomic, clinical, scientific literature) to identify novel biological targets that are implicated in diseases. This significantly speeds up the initial, often time-consuming, phase of drug discovery.\n",
      "    *   **Example:** Companies are using AI to predict which proteins are most likely to be effective drug targets for specific cancers or neurological disorders.\n",
      "*   **De Novo Drug Design:** Instead of screening existing libraries of compounds, AI can now *design entirely new molecules* from scratch that are optimized to bind to a specific target and have desired pharmacological properties (efficacy, safety, solubility).\n",
      "    *   **Example:** Generative AI models can create novel chemical structures with a high probability of success, drastically reducing the number of compounds that need to be synthesized and tested.\n",
      "*   **Predicting Compound Efficacy and Toxicity:** AI models can predict how well a potential drug will work and what its side effects might be *before* it's even synthesized. This helps researchers prioritize the most promising candidates and de-prioritize those likely to fail, saving immense time and resources.\n",
      "    *   **Example:** AI is being used to predict off-target effects or potential liver toxicity of drug candidates early in the process.\n",
      "*   **Repurposing Existing Drugs:** AI can analyze existing drugs and their known mechanisms of action to identify new therapeutic uses for them. This is a faster and less expensive route to new treatments as safety profiles are already established.\n",
      "    *   **Example:** AI has been used to identify existing drugs that might be effective against emerging infectious diseases or rare genetic disorders.\n",
      "*   **Optimizing Clinical Trial Design:** AI can analyze historical clinical trial data and real-world evidence to help design more efficient and effective trials, including identifying the right patient populations and predicting trial outcomes.\n",
      "\n",
      "**Specific Examples and Companies to Watch:**\n",
      "\n",
      "*   **Insilico Medicine:** This company has been a pioneer, using AI for end-to-end drug discovery, from target identification to molecule design. They've had several AI-discovered drug candidates enter clinical trials.\n",
      "*   **Exscientia:** Another leader in AI-driven drug discovery, Exscientia focuses on designing novel molecules for various therapeutic areas and has entered into significant partnerships with major pharmaceutical companies.\n",
      "*   **Recursion Pharmaceuticals:** Recursion uses AI and automation to map human cellular responses to diseases and potential drugs, looking for novel therapeutic interventions.\n",
      "*   **Alphabet's DeepMind (AlphaFold):** While not directly a drug discovery company, AlphaFold's ability to predict protein structures with unprecedented accuracy is a game-changer. Knowing a protein's 3D shape is crucial for understanding its function and designing drugs that can interact with it. This has accelerated research for many drug discovery efforts.\n",
      "*   **Relay Therapeutics:** They focus on using a combination of experimental and computational approaches, including AI, to understand protein motion and design better drugs.\n",
      "\n",
      "**Emerging Trends:**\n",
      "\n",
      "*   **Focus on Undruggable Targets:** AI is increasingly being applied to tackle diseases caused by \"undruggable\" targets – proteins that have been historically difficult to design drugs for due to their complex structures or functions.\n",
      "*   **AI in Antibody Discovery:** AI is accelerating the discovery and engineering of therapeutic antibodies, which are a major class of drugs.\n",
      "*   **Personalized Drug Discovery:** While still nascent, AI holds the promise of enabling drug discovery tailored to an individual's genetic makeup or disease profile.\n",
      "\n",
      "**In summary, AI is not just augmenting drug discovery; it's fundamentally transforming it by making the process faster, more efficient, and capable of exploring entirely new frontiers in molecular design and therapeutic intervention.**\n",
      "\n",
      " ### Session: compaction_demo\n",
      "\n",
      "User > Tell me more about the second development you found.\n",
      "gemini-2.5-flash-lite >  You're likely referring to **De Novo Drug Design** when you ask about the \"second development\" in drug discovery. This is indeed one of the most transformative areas where AI is making a significant impact.\n",
      "\n",
      "Let me elaborate on **De Novo Drug Design:**\n",
      "\n",
      "**What is De Novo Drug Design?**\n",
      "\n",
      "Traditionally, drug discovery involved:\n",
      "1.  **Target Identification:** Finding the biological molecule (like a protein) involved in a disease.\n",
      "2.  **Library Screening:** Testing thousands or millions of existing chemical compounds (from large libraries) to see if any bind to the target.\n",
      "3.  **Lead Optimization:** Taking promising \"hits\" from screening and modifying them to improve their properties.\n",
      "\n",
      "**De Novo drug design** (from Latin, meaning \"from the beginning\") bypasses the extensive library screening. Instead, it uses AI algorithms to **generate entirely new molecular structures** that are specifically designed to interact with a given biological target and possess desired drug-like properties.\n",
      "\n",
      "**How AI Enables De Novo Design:**\n",
      "\n",
      "AI models, particularly **generative models**, are the core of this process. Think of them as highly intelligent \"molecular architects.\" Here's how they work:\n",
      "\n",
      "1.  **Learning Molecular Language:** AI models are trained on vast datasets of known molecules, their structures, properties, and how they interact with biological targets. This allows them to learn the \"language\" of chemistry and understand the rules that govern molecular behavior and drug-likeness.\n",
      "2.  **Defining Design Criteria:** Researchers specify the desired characteristics of the molecule they want to create. This includes:\n",
      "    *   **Binding Affinity:** How strongly it should bind to the target protein.\n",
      "    *   **Selectivity:** How specifically it should bind to the target without hitting other unintended targets (reducing side effects).\n",
      "    *   **Pharmacokinetic Properties (ADMET):** How the drug will be Absorbed, Distributed, Metabolized, Excreted, and its Toxicity profile.\n",
      "    *   **Synthesizability:** The likelihood that the molecule can actually be created in a lab.\n",
      "3.  **Generating Novel Molecules:** Using techniques like **Generative Adversarial Networks (GANs)**, **Variational Autoencoders (VAEs)**, or **Reinforcement Learning**, the AI proposes novel chemical structures that are predicted to meet these criteria.\n",
      "    *   **GANs:** One part of the AI (the \"generator\") creates candidate molecules, while another part (the \"discriminator\") tries to distinguish between real molecules and AI-generated ones. Through this adversarial process, the generator gets better and better at creating realistic and effective molecules.\n",
      "    *   **VAEs:** These models learn a compressed representation (latent space) of molecular structures and can then decode points in this space into new, diverse molecules.\n",
      "    *   **Reinforcement Learning:** The AI explores the chemical space, receiving \"rewards\" for generating molecules that meet the design criteria and \"penalties\" for those that don't, learning to optimize its generation strategy.\n",
      "4.  **Iteration and Refinement:** The process is iterative. The AI generates molecules, they are evaluated (often using AI-based prediction models or initial experimental validation), and the feedback is used to refine the generation process.\n",
      "\n",
      "**Key Advantages of De Novo Drug Design:**\n",
      "\n",
      "*   **Speed:** It dramatically accelerates the hit-finding phase, moving from concept to potential drug candidate much faster than traditional methods.\n",
      "*   **Novelty:** It can discover entirely new chemical scaffolds that might not have been conceived of through human intuition or existing libraries.\n",
      "*   **Optimization:** It's not just about finding a binder; it's about designing molecules with optimized drug-like properties from the outset.\n",
      "*   **Reduced Costs:** By prioritizing more promising candidates and avoiding extensive trial-and-error with less likely compounds, it can significantly reduce R&D expenses.\n",
      "*   **Tackling Difficult Targets:** It offers a powerful approach for designing drugs against \"undruggable\" targets that have proven challenging for traditional methods.\n",
      "\n",
      "**Challenges:**\n",
      "\n",
      "*   **Synthesizability:** Ensuring the generated molecules can actually be synthesized in a lab is still a key challenge, though AI is also being used to predict and optimize synthetic routes.\n",
      "*   **Validation:** Experimental validation is still crucial to confirm the AI's predictions.\n",
      "*   **Data Quality:** The performance of AI models heavily relies on the quality and comprehensiveness of the training data.\n",
      "\n",
      "**In essence, de novo drug design powered by AI represents a paradigm shift, moving from searching for drugs to creating them with precision and intent.** It's a rapidly evolving field that holds immense promise for bringing new medicines to patients faster.\n",
      "\n",
      " ### Session: compaction_demo\n",
      "\n",
      "User > Who are the main companies involved in that?\n",
      "gemini-2.5-flash-lite >  The landscape of companies involved in de novo drug design is dynamic and growing, encompassing both specialized AI-driven biotech firms and established pharmaceutical giants leveraging these technologies. Here are some of the key players and categories:\n",
      "\n",
      "**1. Dedicated AI-Driven Drug Discovery Companies:** These companies were built from the ground up with AI at their core.\n",
      "\n",
      "*   **Insilico Medicine:** A major player that uses its AI platform to cover the entire drug discovery pipeline, from target identification to drug candidate generation and preclinical development. They have advanced several AI-discovered candidates into clinical trials.\n",
      "*   **Exscientia:** Another leader focused on AI-driven design of novel molecules. They partner extensively with large pharmaceutical companies and have a pipeline of AI-designed drugs in development.\n",
      "*   **Atomwise:** They use deep learning for small molecule drug discovery, including de novo design, and have collaborations with numerous research institutions and pharmaceutical companies.\n",
      "*   **Recursion Pharmaceuticals:** While their platform is broader, integrating AI with automation to map cellular biology and discover therapies, de novo design is a component of their approach to identifying novel drug candidates.\n",
      "*   **Schrödinger:** Though not exclusively an AI company, Schrödinger has a long-standing reputation in computational chemistry and physics-based drug discovery. They have increasingly integrated machine learning and AI into their platform for de novo design and property prediction.\n",
      "*   **Relay Therapeutics:** Focuses on understanding protein motion and using computational approaches, including AI, to design novel therapeutics.\n",
      "*   **Nuritas:** Uses AI and machine learning to discover novel peptides with therapeutic potential, often from natural sources, but the discovery and optimization involve AI-driven design principles.\n",
      "\n",
      "**2. Major Pharmaceutical Companies Adopting AI for De Novo Design:** The \"Big Pharma\" are heavily investing in and collaborating with AI companies, or building their own internal AI capabilities.\n",
      "\n",
      "*   **Pfizer:** Has been actively exploring AI for various aspects of drug discovery, including de novo design.\n",
      "*   **Novartis:** Has a strong focus on digital transformation and AI, with initiatives in AI-driven drug discovery.\n",
      "*   **Merck:** Is investing in AI and machine learning to accelerate its R&D efforts, including molecule design.\n",
      "*   **Johnson & Johnson:** Has several collaborations and internal teams working on AI for drug discovery.\n",
      "*   **AstraZeneca:** Actively utilizes AI and machine learning to enhance its discovery and development processes.\n",
      "*   **Roche:** A major player in utilizing computational methods and AI in its R&D.\n",
      "*   **Bayer:** Is partnering with AI companies and investing in AI capabilities for drug discovery.\n",
      "\n",
      "**3. Technology Companies and Cloud Providers Enabling AI Drug Discovery:**\n",
      "\n",
      "While not directly designing drugs, these companies provide the foundational infrastructure and tools that make de novo design possible.\n",
      "\n",
      "*   **Google (DeepMind):** As mentioned with AlphaFold, their contributions to understanding protein structures are foundational for AI-driven drug design.\n",
      "*   **Microsoft:** Offers cloud computing resources and AI tools that are crucial for large-scale drug discovery simulations and model training.\n",
      "*   **Amazon Web Services (AWS):** Provides similar cloud infrastructure and AI/ML services.\n",
      "\n",
      "**4. Academic and Research Institutions:** Many universities and research centers are at the forefront of developing new AI algorithms and methodologies for de novo drug design, often collaborating with industry.\n",
      "\n",
      "**Key Trends in the Company Landscape:**\n",
      "\n",
      "*   **Partnerships and Acquisitions:** Large pharma companies frequently partner with or acquire AI-focused biotech firms to gain access to cutting-edge technology.\n",
      "*   **In-house AI Teams:** Many large pharmaceutical companies are building significant internal AI/ML teams to develop their own proprietary platforms.\n",
      "*   **Focus on Specific Disease Areas:** Some AI companies are specializing in particular therapeutic areas (e.g., oncology, rare diseases) where they can apply their de novo design capabilities.\n",
      "*   **Integration with Other AI Applications:** Companies are increasingly looking to integrate de novo design with other AI applications, such as predictive toxicology and clinical trial optimization.\n",
      "\n",
      "The field is highly competitive, with constant innovation and new players emerging. It's a space where AI is truly moving from the theoretical to tangible drug candidates entering human trials.\n"
     ]
    }
   ],
   "source": [
    "# Turn 1\n",
    "await run_session(\n",
    "    research_runner_compacting,\n",
    "    \"What is the latest news about AI in healthcare?\",\n",
    "    \"compaction_demo\",\n",
    ")\n",
    "\n",
    "# Turn 2\n",
    "await run_session(\n",
    "    research_runner_compacting,\n",
    "    \"Are there any new developments in drug discovery?\",\n",
    "    \"compaction_demo\",\n",
    ")\n",
    "\n",
    "# Turn 3 - Compaction should trigger after this turn!\n",
    "await run_session(\n",
    "    research_runner_compacting,\n",
    "    \"Tell me more about the second development you found.\",\n",
    "    \"compaction_demo\",\n",
    ")\n",
    "\n",
    "# Turn 4\n",
    "await run_session(\n",
    "    research_runner_compacting,\n",
    "    \"Who are the main companies involved in that?\",\n",
    "    \"compaction_demo\",\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "82e3799e",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "--- Searching for Compaction Summary Event ---\n",
      "\n",
      "✅ SUCCESS! Found the Compaction Event:\n",
      "  Author: user\n",
      "\n",
      " Compacted information: model_version=None content=None grounding_metadata=None partial=None turn_complete=None finish_reason=None error_code=None error_message=None interrupted=None custom_metadata=None usage_metadata=None live_session_resumption_update=None input_transcription=None output_transcription=None avg_logprobs=None logprobs_result=None cache_metadata=None citation_metadata=None invocation_id='7433fb50-ff6f-4cf4-93c8-752cf5c9fe33' author='user' actions=EventActions(skip_summarization=None, state_delta={}, artifact_delta={}, transfer_to_agent=None, escalate=None, requested_auth_configs={}, requested_tool_confirmations={}, compaction={'start_timestamp': 1762907685.349911, 'end_timestamp': 1762907692.514615, 'compacted_content': {'parts': [{'function_call': None, 'code_execution_result': None, 'executable_code': None, 'file_data': None, 'function_response': None, 'inline_data': None, 'text': 'The user inquired about the latest news in AI in healthcare. The AI agent provided a comprehensive overview, highlighting advancements in drug discovery, medical imaging, personalized treatment, and administrative efficiency. It also discussed emerging trends like generative AI, explainable AI, ethical considerations, and AI\\'s role in mental health and genomics. Challenges such as data privacy, bias, regulation, integration, and cost were also noted.\\n\\nFollowing this, the user asked for more details on new developments in drug discovery. The AI agent confirmed that AI is a major driver, listing accelerated target identification, *de novo* drug design, predicting compound efficacy/toxicity, repurposing existing drugs, and optimizing clinical trials as key AI-powered breakthroughs. Specific companies like Insilico Medicine, Exscientia, Recursion Pharmaceuticals, Alphabet\\'s DeepMind (AlphaFold), and Relay Therapeutics were mentioned as leaders. Emerging trends in tackling \"undruggable\" targets, AI in antibody discovery, and personalized drug discovery were also covered.\\n\\nThe user then requested further information on the \"second development\" mentioned, which the AI identified as **De Novo Drug Design**. The AI explained that this process involves AI algorithms generating entirely new molecular structures specifically designed to interact with a biological target and possess desired drug-like properties, bypassing traditional library screening. It detailed how generative AI models (like GANs and VAEs) learn molecular language, use defined design criteria (binding affinity, selectivity, ADMET, synthesizability), and iteratively generate novel molecules. The advantages highlighted were speed, novelty, optimization, reduced costs, and tackling difficult targets, while challenges included synthesizability, validation, and data quality. The AI concluded by stating that de novo drug design powered by AI is a paradigm shift in drug creation.', 'thought': None, 'thought_signature': None, 'video_metadata': None}], 'role': 'model'}}, end_of_agent=None, agent_state=None, rewind_before_invocation_id=None) long_running_tool_ids=set() branch=None id='765f6edc-6c7e-4b60-a9ac-785036b42810' timestamp=1762907698.076528\n"
     ]
    }
   ],
   "source": [
    "# Get the final session state\n",
    "final_session = await session_service.get_session(\n",
    "    app_name=research_runner_compacting.app_name,\n",
    "    user_id=USER_ID,\n",
    "    session_id=\"compaction_demo\",\n",
    ")\n",
    "\n",
    "print(\"--- Searching for Compaction Summary Event ---\")\n",
    "found_summary = False\n",
    "for event in final_session.events:\n",
    "    # Compaction events have a 'compaction' attribute\n",
    "    if event.actions and event.actions.compaction:\n",
    "        print(\"\\n✅ SUCCESS! Found the Compaction Event:\")\n",
    "        print(f\"  Author: {event.author}\")\n",
    "        print(f\"\\n Compacted information: {event}\")\n",
    "        found_summary = True\n",
    "        break\n",
    "\n",
    "if not found_summary:\n",
    "    print(\n",
    "        \"\\n❌ No compaction event found. Try increasing the number of turns in the demo.\"\n",
    "    )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "75ba78b2",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "✅ Tools created.\n"
     ]
    }
   ],
   "source": [
    "# Define scope levels for state keys (following best practices)\n",
    "USER_NAME_SCOPE_LEVELS = (\"temp\", \"user\", \"app\")\n",
    "\n",
    "\n",
    "# This demonstrates how tools can write to session state using tool_context.\n",
    "# The 'user:' prefix indicates this is user-specific data.\n",
    "def save_userinfo(\n",
    "    tool_context: ToolContext, user_name: str, country: str\n",
    ") -> Dict[str, Any]:\n",
    "    \"\"\"\n",
    "    Tool to record and save user name and country in session state.\n",
    "\n",
    "    Args:\n",
    "        user_name: The username to store in session state\n",
    "        country: The name of the user's country\n",
    "    \"\"\"\n",
    "    # Write to session state using the 'user:' prefix for user data\n",
    "    tool_context.state[\"user:name\"] = user_name\n",
    "    tool_context.state[\"user:country\"] = country\n",
    "\n",
    "    return {\"status\": \"success\"}\n",
    "\n",
    "\n",
    "# This demonstrates how tools can read from session state.\n",
    "def retrieve_userinfo(tool_context: ToolContext) -> Dict[str, Any]:\n",
    "    \"\"\"\n",
    "    Tool to retrieve user name and country from session state.\n",
    "    \"\"\"\n",
    "    # Read from session state\n",
    "    user_name = tool_context.state.get(\"user:name\", \"Username not found\")\n",
    "    country = tool_context.state.get(\"user:country\", \"Country not found\")\n",
    "\n",
    "    return {\"status\": \"success\", \"user_name\": user_name, \"country\": country}\n",
    "\n",
    "\n",
    "print(\"✅ Tools created.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "f9a715dd",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "✅ Agent with session state tools initialized!\n"
     ]
    }
   ],
   "source": [
    "# Configuration\n",
    "APP_NAME = \"default\"\n",
    "USER_ID = \"default\"\n",
    "MODEL_NAME = \"gemini-2.5-flash-lite\"\n",
    "\n",
    "# Create an agent with session state tools\n",
    "root_agent = LlmAgent(\n",
    "    model=Gemini(model=\"gemini-2.5-flash-lite\", retry_options=retry_config),\n",
    "    name=\"text_chat_bot\",\n",
    "    description=\"\"\"A text chatbot.\n",
    "    Tools for managing user context:\n",
    "    * To record username and country when provided use `save_userinfo` tool. \n",
    "    * To fetch username and country when required use `retrieve_userinfo` tool.\n",
    "    \"\"\",\n",
    "    tools=[save_userinfo, retrieve_userinfo],  # Provide the tools to the agent\n",
    ")\n",
    "\n",
    "# Set up session service and runner\n",
    "session_service = InMemorySessionService()\n",
    "runner = Runner(agent=root_agent, session_service=session_service, app_name=\"default\")\n",
    "\n",
    "print(\"✅ Agent with session state tools initialized!\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "4ea1cb23",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " ### Session: state-demo-session\n",
      "\n",
      "User > Hi there, how are you doing today? What is my name?\n",
      "gemini-2.5-flash-lite >  Hello! I'm doing well, thank you for asking. I can't recall your name at the moment. Would you mind telling me what it is?\n",
      "\n",
      "\n",
      "User > My name is Manan. I'm from India.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Warning: there are non-text parts in the response: ['function_call'], returning concatenated text result from text parts. Check the full candidates.content.parts accessor to get the full model response.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "gemini-2.5-flash-lite >  It's a pleasure to meet you, Manan! I'll keep that information in mind.\n",
      "\n",
      "gemini-2.5-flash-lite >  I've saved your name as Manan and your country as India. How else may I assist you today?\n",
      "\n",
      "\n",
      "User > What is my name? Which country am I from?\n",
      "gemini-2.5-flash-lite >  Your name is Manan and you are from India.\n"
     ]
    }
   ],
   "source": [
    "# Test conversation demonstrating session state\n",
    "await run_session(\n",
    "    runner,\n",
    "    [\n",
    "        \"Hi there, how are you doing today? What is my name?\",  # Agent shouldn't know the name yet\n",
    "        \"My name is Manan. I'm from India.\",  # Provide name - agent should save it\n",
    "        \"What is my name? Which country am I from?\",  # Agent should recall from session state\n",
    "    ],\n",
    "    \"state-demo-session\",\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "bc3632f4",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Session State Contents:\n",
      "{'user:name': 'Manan', 'user:country': 'India'}\n",
      "\n",
      "🔍 Notice the 'user:name' and 'user:country' keys storing our data!\n"
     ]
    }
   ],
   "source": [
    "# Retrieve the session and inspect its state\n",
    "session = await session_service.get_session(\n",
    "    app_name=APP_NAME, user_id=USER_ID, session_id=\"state-demo-session\"\n",
    ")\n",
    "\n",
    "print(\"Session State Contents:\")\n",
    "print(session.state)\n",
    "print(\"\\n🔍 Notice the 'user:name' and 'user:country' keys storing our data!\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "0be0eb10",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " ### Session: new-isolated-session\n",
      "\n",
      "User > Hi there, how are you doing today? What is my name?\n",
      "gemini-2.5-flash-lite >  Hello! I'm doing great. I can't recall your name at the moment. Can you please tell me what it is? If you'd like me to remember it for our future conversations, I can save it along with your country.\n"
     ]
    }
   ],
   "source": [
    "# Start a completely new session - the agent won't know our name\n",
    "await run_session(\n",
    "    runner,\n",
    "    [\"Hi there, how are you doing today? What is my name?\"],\n",
    "    \"new-isolated-session\",\n",
    ")\n",
    "\n",
    "# Expected: The agent won't know the name because this is a different session"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "740fc2ca",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "New Session State:\n",
      "{'user:name': 'Manan', 'user:country': 'India'}\n"
     ]
    }
   ],
   "source": [
    "# Check the state of the new session\n",
    "session = await session_service.get_session(\n",
    "    app_name=APP_NAME, user_id=USER_ID, session_id=\"new-isolated-session\"\n",
    ")\n",
    "\n",
    "print(\"New Session State:\")\n",
    "print(session.state)\n",
    "\n",
    "# Note: Depending on implementation, you might see shared state here.\n",
    "# This is where the distinction between session-specific and user-specific state becomes important."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "c797f692",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "✅ Cleaned up old database files\n"
     ]
    }
   ],
   "source": [
    "# Clean up any existing database to start fresh (if Notebook is restarted)\n",
    "import os\n",
    "\n",
    "if os.path.exists(\"my_agent_data.db\"):\n",
    "    os.remove(\"my_agent_data.db\")\n",
    "print(\"✅ Cleaned up old database files\")"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "adk",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.14"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
